32Biosciences is focused on gastrointestinal (GI) diseases initially centered on the colon, addressing high unmet medical needs in prevention and treatment with a first-in-class therapeutic and a novel discovery platform.
At 32 Biosciences, our approach is grounded in decades of visionary research led by our renowned scientific co-founders—John Alverdy, MD, Eugene Chang, MD, and Joseph Pierre, PhD. As globally recognized experts in gastrointestinal disease, their pathbreaking work includes over 650 peer-reviewed publications and $126M in NIH funding, forming the foundation of our innovative solutions.
Our transformative platform technologies are further propelled by strategic collaborations with the University of Chicago’s Duchossois Family Institute and Pritzker School of Molecular Engineering.
32 Biosciences is developing first-in-class therapeutics designed to act at the GI mucosal interface before inflammatory amplification.
CS-0003: Three Mechanistic Pillars
Functional Biological Measurement
GB-0001 is a stool-based functional metabolomics tool designed to quantify signatures associated with gut microbial ecosystem activity, host-microbe interaction, and GI mucosal-immune biology.